HUE042919T2 - Genetikai immunizáció sejthez kapcsolódó antigének - például P2X7, CXCR7 vagy CXCR4 - elleni immunglobulinok elõállítására - Google Patents

Genetikai immunizáció sejthez kapcsolódó antigének - például P2X7, CXCR7 vagy CXCR4 - elleni immunglobulinok elõállítására

Info

Publication number
HUE042919T2
HUE042919T2 HUE09799348A HUE09799348A HUE042919T2 HU E042919 T2 HUE042919 T2 HU E042919T2 HU E09799348 A HUE09799348 A HU E09799348A HU E09799348 A HUE09799348 A HU E09799348A HU E042919 T2 HUE042919 T2 HU E042919T2
Authority
HU
Hungary
Prior art keywords
cxcr7
cxcr4
associated antigens
against cell
genetic immunization
Prior art date
Application number
HUE09799348A
Other languages
English (en)
Inventor
Toon Laeremans
Catelijne Stortelers
Friedrich Nolte
Maria Gonzalez
Joana Assuncao
Rompaey Philippe Van
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of HUE042919T2 publication Critical patent/HUE042919T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HUE09799348A 2008-12-19 2009-12-21 Genetikai immunizáció sejthez kapcsolódó antigének - például P2X7, CXCR7 vagy CXCR4 - elleni immunglobulinok elõállítására HUE042919T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20318808P 2008-12-19 2008-12-19

Publications (1)

Publication Number Publication Date
HUE042919T2 true HUE042919T2 (hu) 2019-07-29

Family

ID=42269156

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE09799348A HUE042919T2 (hu) 2008-12-19 2009-12-21 Genetikai immunizáció sejthez kapcsolódó antigének - például P2X7, CXCR7 vagy CXCR4 - elleni immunglobulinok elõállítására

Country Status (11)

Country Link
US (2) US9260508B2 (hu)
EP (2) EP2370465B1 (hu)
JP (2) JP2012512646A (hu)
CN (2) CN107011434B (hu)
AU (2) AU2009329501B2 (hu)
CA (1) CA2747644C (hu)
CY (1) CY1122131T1 (hu)
DK (1) DK2370465T3 (hu)
ES (1) ES2729320T3 (hu)
HU (1) HUE042919T2 (hu)
WO (1) WO2010070145A2 (hu)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
CN102099378B (zh) 2008-05-16 2016-01-20 埃博灵克斯股份有限公司 针对CXCR4和其他GPCRs的氨基酸序列以及包含所述氨基酸序列的多肽
CN107011434B (zh) 2008-12-19 2021-02-19 埃博灵克斯股份有限公司 用于产生针对细胞相关抗原如p2x7、cxcr7或cxcr4的免疫球蛋白的基因免疫
WO2011083141A2 (en) * 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
WO2011117423A1 (en) 2010-03-26 2011-09-29 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
MX343085B (es) 2010-11-08 2016-10-24 Novartis Ag Polipeptidos que se enlazan a cxcr2.
PT2686347T (pt) * 2011-03-16 2018-07-05 Argenx Bvba Anticorpos dirigidos contra cd70
US20150158948A9 (en) 2011-03-28 2015-06-11 Francis Descamps Bispecific anti-cxcr7 immunoglobulin single variable domains
EP3388451A1 (en) 2011-09-29 2018-10-17 Apo-T B.V. Multi specific binding molecules targeting aberrant cells
WO2013105856A1 (en) 2012-01-13 2013-07-18 Apo-T B.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety
EP2855518A1 (en) * 2012-06-01 2015-04-08 Ablynx N.V. P2x7 receptor antagonists and agonists
AU2013281327A1 (en) * 2012-06-26 2015-01-22 Apo-T B.V. Binding molecules targeting pathogens
HUE035315T2 (hu) 2013-01-30 2018-05-02 Vib Vzw Új kiméra polipeptidek szkrínelésre és gyógyszerkutatási célokra
PL2953973T3 (pl) 2013-02-05 2020-01-31 Vib Vzw Środki wiążące muskarynowy receptor acetylocholiny i ich zastosowania
GB2517953A (en) * 2013-09-05 2015-03-11 Argen X Bv Antibodies to complex targets
AU2015217846B2 (en) 2014-01-30 2019-10-10 The Board Of Trustees Of The Leland Stanford Junior University Opioid receptor binding agents and uses thereof
WO2016012363A1 (en) 2014-07-22 2016-01-28 Vib Vzw Methods to select for agents that stabilize protein complexes
CN104479016A (zh) * 2014-12-31 2015-04-01 广州吉赛生物科技有限公司 利用dna纹身免疫制备抗体的方法
WO2017081265A1 (en) * 2015-11-12 2017-05-18 Ablynx Nv Improved p2x7 receptor binders and polypeptides comprising the same
WO2020046982A1 (en) * 2018-08-27 2020-03-05 University Of Virginia Patent Foundation Compositions and methods for preventing and treating virus infection
US11312754B2 (en) * 2019-05-31 2022-04-26 Access Business Group International Llc Sunflower seed protein-derived peptides
US20220251518A1 (en) * 2019-07-08 2022-08-11 Terumo Kabushik Kaisha Hybridoma, method for making the same, monoclonal antibody, and method for making the same
WO2021140205A1 (en) 2020-01-10 2021-07-15 Confo Therapeutics N.V. Methods for generating antibodies and antibody fragments and libraries comprising same
EP4334515A1 (en) * 2021-05-03 2024-03-13 Twist Bioscience Corporation Variant nucleic acid libraries for glycans
EP4334516A1 (en) * 2021-05-03 2024-03-13 Twist Bioscience Corporation Variant nucleic acid libraries for ion channels
CN117003876B (zh) * 2023-08-31 2024-06-18 恺佧生物科技(上海)有限公司 一种Anti-CXCR4膜蛋白抗体及其制备方法和应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
ATE427968T1 (de) 1992-08-21 2009-04-15 Univ Bruxelles Immunoglobuline ohne leichtkette
US6146826A (en) 1993-09-10 2000-11-14 The Trustees Of Columbia University In The City Of New York Green fluorescent protein
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
AU4964896A (en) 1995-01-19 1996-08-07 Research Foundation Of The State University Of New York, The Genes encoding an insect calcium channel
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US5693492A (en) 1995-05-05 1997-12-02 Merck & Co., Inc. DNA encoding glutamate gated chloride channels
CA2232727C (en) 1995-09-22 2002-03-26 Novo Nordisk A/S Novel variants of green fluorescent protein, gfp
US6027881A (en) 1996-05-08 2000-02-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Mutant Aequorea victoria fluorescent proteins having increased cellular fluorescence
US6124128A (en) 1996-08-16 2000-09-26 The Regents Of The University Of California Long wavelength engineered fluorescent proteins
WO1998021355A1 (en) 1996-11-15 1998-05-22 Life Technologies, Inc. Mutants of green fluorescent protein
AU2152299A (en) 1997-10-27 1999-05-24 Unilever Plc Multivalent antigen-binding proteins
BR9907241A (pt) 1998-01-26 2000-10-17 Unilever Nv Biblioteca de expressão, processo para preparar a mesma, uso de uma fonte não imunizada de sequências de ácido nucleico, e, processos para preparar fragmentos de anticorpos e, para preparar um anticorpo
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
ATE276359T1 (de) 1999-01-19 2004-10-15 Unilever Nv Verfahren zur herstellung von antikörperfragmenten
AUPP991199A0 (en) * 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
GB9922124D0 (en) 1999-09-17 1999-11-17 Pfizer Ltd Phosphodiesterase enzymes
DE60030323T2 (de) 1999-12-24 2007-10-11 Genentech, Inc., South San Francisco Verfahren und verbindungen zur verlängerung der halbwertzeiten bei der ausscheidung von biowirksamen verbindungen
CA2380443C (en) 2000-05-26 2013-03-12 Ginette Dubuc Single-domain antigen-binding antibody fragments derived from llama antibodies
EP1328626B1 (en) 2000-05-26 2013-04-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
ATE418565T1 (de) * 2001-01-17 2009-01-15 Intreat Pty Ltd Antikörper gegen nichtfunktionelle p 2 x 7 rezeptoren, diagnose und behandlung von krebs und anderen leiden
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
US7371849B2 (en) 2001-09-13 2008-05-13 Institute For Antibodies Co., Ltd. Methods of constructing camel antibody libraries
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US20050214857A1 (en) * 2001-12-11 2005-09-29 Algonomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
JP4323317B2 (ja) 2001-12-21 2009-09-02 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー（ヴェーイーベー・ヴェーゼットウェー） 可変領域配列のクローニング方法
EP1461085A2 (en) 2002-01-03 2004-09-29 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Immunoconjugates useful for treatment of tumours
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
ATE528648T1 (de) 2002-12-03 2011-10-15 Ucb Pharma Sa Verfahren zum nachweis antikörper-herstellender zellen
JP4490290B2 (ja) 2002-12-31 2010-06-23 ネクター セラピューティクス アラバマ，コーポレイション 加水分解安定性マレイミド末端ポリマー
EP1615991A4 (en) * 2003-04-03 2007-12-19 Bristol Myers Squibb Co POLYNUCLEOTIDE ENCODING A NEW HUMAN P2X7 SPLICE VARIANT CALLED HBMYP2X7V
GB0312321D0 (en) * 2003-05-29 2003-07-02 Astrazeneca Ab New combination
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
ATE554390T1 (de) 2003-08-20 2012-05-15 Ucb Pharma Sa Verfahren zur gewinnung von antikörpern
DE60334645D1 (de) 2003-11-07 2010-12-02 Ablynx Nv Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
US20060008601A1 (en) 2004-06-25 2006-01-12 Zeik Douglas B Flexible laminate having an integrated pressure release valve
KR101443473B1 (ko) 2004-07-22 2014-09-22 에라스무스 유니버시티 메디컬 센터 로테르담 Ｖh 결합 영역의 분리 방법
JP5113523B2 (ja) 2004-10-13 2013-01-09 アブリンクス ナームローゼ フェンノートシャップ アミロイド−βに対するナノ抗体及びアルツハイマー病のような神経変性疾患の治療のためのナノ抗体ＴＭを含むポリペプチド
WO2006040154A2 (en) 2004-10-14 2006-04-20 Dublin City University Prokaryotic two hybrid system
WO2006079372A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
CA2624781A1 (en) 2005-10-11 2007-04-19 Ablynx N.V. Nanobodies tm and polypeptides against egfr and igf-ir
EP2040995A1 (en) 2006-06-26 2009-04-01 Aida Centre, S.L. Blister package integrating rfid based tags
WO2008020079A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
US8067550B2 (en) * 2006-10-10 2011-11-29 Biosceptre International Limited Hybridomas producing antibodies against non functional P2X7 receptor
AU2007336242B2 (en) 2006-12-19 2012-08-30 Ablynx N.V. Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
WO2009068630A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Immunoglobulin constructs
JP2011516603A (ja) 2008-04-17 2011-05-26 アブリンクス エン．ヴェー． 血清タンパク質と結合することが可能なペプチド、並びにこれを含む化合物、構築物及びポリペプチド
CN102099378B (zh) * 2008-05-16 2016-01-20 埃博灵克斯股份有限公司 针对CXCR4和其他GPCRs的氨基酸序列以及包含所述氨基酸序列的多肽
CN107011434B (zh) 2008-12-19 2021-02-19 埃博灵克斯股份有限公司 用于产生针对细胞相关抗原如p2x7、cxcr7或cxcr4的免疫球蛋白的基因免疫
EP2855518A1 (en) * 2012-06-01 2015-04-08 Ablynx N.V. P2x7 receptor antagonists and agonists

Also Published As

Publication number Publication date
JP2012512646A (ja) 2012-06-07
AU2016200146B2 (en) 2018-02-01
EP3470425A3 (en) 2019-07-17
EP3470425A2 (en) 2019-04-17
ES2729320T3 (es) 2019-10-31
CN107011434B (zh) 2021-02-19
CY1122131T1 (el) 2020-11-25
CN107011434A (zh) 2017-08-04
CA2747644A1 (en) 2010-06-24
AU2016200146A1 (en) 2016-02-04
JP2015155429A (ja) 2015-08-27
US9260508B2 (en) 2016-02-16
WO2010070145A2 (en) 2010-06-24
CA2747644C (en) 2023-01-24
JP6034435B2 (ja) 2016-11-30
CN102257003A (zh) 2011-11-23
DK2370465T3 (da) 2019-05-06
AU2009329501A1 (en) 2010-06-24
US10023633B2 (en) 2018-07-17
WO2010070145A3 (en) 2010-12-02
EP2370465B1 (en) 2019-01-23
CN102257003B (zh) 2017-04-05
EP2370465A2 (en) 2011-10-05
AU2016200146B9 (en) 2018-02-15
US20100173799A1 (en) 2010-07-08
AU2009329501B2 (en) 2015-11-26
US20160264664A1 (en) 2016-09-15

Similar Documents

Publication Publication Date Title
HUE042919T2 (hu) Genetikai immunizáció sejthez kapcsolódó antigének - például P2X7, CXCR7 vagy CXCR4 - elleni immunglobulinok elõállítására
HK1223382A1 (zh) 免疫療法的新型免疫抗原表位
IL229512A (en) Anti-vegf antibodies
IL212066A (en) 4cxcr antibodies, preparations containing them, processes for their production and selection and use for cancer treatment
EP2152290A4 (en) METHOD FOR THE ADMINISTRATION OF ANTI-IL-5 ANTIBODIES
MY178926A (en) Bispecific anti-vegf/anti-ang-2 antibodies
IL222116A (en) Two-valent, bi-specific antibody against 2-ang / vegf
IL217827A0 (en) Muc1 antibodies, nucleic acids encoding the same and methods for producing the same
EP2349331A4 (en) HUMANIZED ANTIBODIES TO IL-6
WO2011110642A3 (en) Monoclonal antibodies against c-met
ZA201005348B (en) Humanized anti-c5ar antibodies
SI2376116T1 (sl) Anti-IGF protitelesa
PL2630108T3 (pl) Sposób wytwarzania 2,3,3,3-tetrafluoropropenu
IL206715A (en) Anti-mif anti-mif antibodies, medicinal preparations containing them, their use and methods for their preparation
IL211010A (en) Antibody, antibody hybridoma, antibody-containing conjugate, antibody-containing drug and / or conjugate and their uses
SG178886A1 (en) Humanized anti-cdcp1 antibodies
EP2259795A4 (en) ANTI-VEGF ANTIBODY
IL219801A (en) Anti-a4 antibody. 4c isolates, vectors encoded by them, methods of preparation, preparations containing them and their use
IL205073A (en) 2 bst antibodies, methods of making them, medicinal preparations containing them and their use
EP2217626A4 (en) EPITOP FOR NEUTRALIZING ANTIBODIES
EP2485752A4 (en) FUSION - PROTEIN VACCINES. ENTEROXROGENIC COLI
HK1182745A1 (zh) 用於產生、確認和使用單克隆抗體的方法和系統
HU0700023D0 (en) Method for producing water-proof, heat-resistant, light construction furniture elements